Mechanism of HIV antiretroviral drugs progress toward drug resistance

Fundamental and Clinical Pharmacology

Volumn 26, Issue 1, 2012, Pages 146-161

  Ammaranond, Palanee ^a   Sanguansittianan, Sayompoo ^a  

^a CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

Antiretroviral; Drug resistance; HIV

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; DARUNAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; ETRAVIRINE; FOSAMPRENAVIR; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; INDINAVIR; INTEGRASE INHIBITOR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RALTEGRAVIR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR DISOPROXIL; TIPRANAVIR; TNTELENCE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZALCITABINE; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; DRUG MECHANISM; DRUG TARGETING; DRUG TREATMENT FAILURE; GENETIC VARIABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MUTATION RATE; NONHUMAN; PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION; TREATMENT OUTCOME; VIRUS REPLICATION; VIRUS STRAIN;

ANIMALS; ANTI-HIV AGENTS; DRUG RESISTANCE, MULTIPLE, VIRAL; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV-1; HUMANS; MUTATION; RNA, VIRAL; TREATMENT OUTCOME; VIRUS REPLICATION;

EID: 84855654765     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2011.01009.x     Document Type: Review

References (168)

1. Masur H., Michelis M.A., Greene J.B. et al. An outbreak of community-acquired Pneumocystis carinii pneumonia: initial manifestation of cellular immune dysfunction. N. Engl. J. Med. (1981) 305 1431-1438.
2. Fuchs D., Wachter H., Wille R. AIDS in haemophiliacs, parenteral drug abusers, and homosexuals. Lancet (1986) 1 324.
3. Rubinstein A., Sicklick M., Gupta A. et al. Acquired immunodeficiency with reversed T4/T8 ratios in infants born to promiscuous and drug-addicted mothers. JAMA (1983) 249 2350-2356.
4. Blattner W.A. HIV epidemiology: past, present, and future. FASEB J. (1991) 5 2340-2348.
5. Friedland G.H., Klein R.S. Transmission of the human immunodeficiency virus. N. Engl. J. Med. (1987) 317 1125-1135.
6. Scott G.B., Buck B.E., Leterman J.G., Bloom F.L., Parks W.P. Acquired immunodeficiency syndrome in infants. N. Engl. J. Med. (1984) 310 76-81.
7. Barre-Sinoussi F., Chermann J.C., Rey F. et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science (1983) 220 868-871.
8. Gallo R.C., Salahuddin S.Z., Popovic M. et al. Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science (1984) 224 500-503.
9. UNAIDS. Global summary of the HIV/AIDS epidemic in 2004, Geneva, 2004.
10. Sarafianos S.G., Marchand B., Das K. et al. Structure and function of HIV-1 reverse transcriptase: molecular mechanisms of polymerization and inhibition. J. Mol. Biol. (2009) 385 693-713.
11. Sevilya Z., Loya S., Adir N., Hizi A. The ribonuclease H activity of the reverse transcriptases of human immunodeficiency viruses type 1 and type 2 is modulated by residue 294 of the small subunit. Nucleic Acids Res. (2003) 31 1481-1487.
12. Sevilya Z., Loya S., Duvshani A., Adir N., Hizi A. Mutagenesis of cysteine 280 of the reverse transcriptase of human immunodeficiency virus type-1: the effects on the ribonuclease H activity. J. Mol. Biol. (2003) 327 19-30.
13. Wapling J., Moore K.L., Sonza S., Mak J., Tachedjian G. Mutations that abrogate human immunodeficiency virus type 1 reverse transcriptase dimerization affect maturation of the reverse transcriptase heterodimer. J. Virol. (2005) 79 10247-10257.
14. Abram M.E., Parniak M.A. Virion instability of human immunodeficiency virus type 1 reverse transcriptase (RT) mutated in the protease cleavage site between RT p51 and the RT RNase H domain. J. Virol. (2005) 79 11952-11961.
15. Rezende L.F., Prasad V.R. Nucleoside-analog resistance mutations in HIV-1 reverse transcriptase and their influence on polymerase fidelity and viral mutation rates. Int. J. Biochem. Cell Biol. (2004) 36 1716-1734.
16. Kandathil A.J., Joseph A.P., Kannangai R. et al. HIV reverse transcriptase: structural interpretation of drug resistant genetic variants from India. Bioinformation (2009) 4 36-45.
17. Huang H., Harrison S.C., Verdine G.L. Trapping of a catalytic HIV reverse transcriptase*template: primer complex through a disulfide bond. Chem. Biol. (2000) 7 355-364.
18. Khandazhinskaya A.L., Yanvarev D.V., Jasko M.V. et al. 5′-aminocarbonyl phosphonates as new zidovudine depot forms: antiviral properties, intracellular transformations, and pharmacokinetic parameters. Drug Metab. Dispos. (2009) 37 494-501.
19. Yarchoan R., Mitsuya H., Thomas R.V. et al. In vivo activity against HIV and favorable toxicity profile of 2′, 3′-dideoxyinosine. Science (1989) 245 412-415.
20. Opii W.O., Sultana R., Abdul H.M., Ansari M.A., Nath A., Butterfield D.A. Oxidative stress and toxicity induced by the nucleoside reverse transcriptase inhibitor (NRTI) - 2′, 3′-dideoxycytidine (ddC): relevance to HIV-dementia. Exp. Neurol. (2007) 204 29-38.
21. Gadthula S., Chu C.K., Schinazi R.F. Synthesis and anti-HIV activity of beta-D-3′-azido-2′, 3′-unsaturated nucleosides and beta-D-3′-azido-3′-deoxyribofuranosylnucleosides. Nucleosides Nucleotides Nucleic Acids (2005) 24 1707-1727.
22. Gibbs J.E., Rashid T., Thomas S.A. Effect of transport inhibitors and additional anti-HIV drugs on the movement of lamivudine (3TC) across the guinea pig brain barriers. J. Pharmacol. Exp. Ther. (2003) 306 1035-1041.
23. Gulick R.M. New antiretroviral drugs. Clin. Microbiol. Infect. (2003) 9 186-193.
24. Menendez-Arias L. Mechanisms of resistance to nucleoside analogue inhibitors of HIV-1 reverse transcriptase. Virus Res. (2008) 134 124-146.
25. Wainberg M.A., Gu Z., Gao Q. et al. Clinical correlates and molecular basis of HIV drug resistance. J. Acquir. Immune Defic. Syndr. (1993) 6(Suppl 1) S36-S46.
26. Richman D.D. Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents. Antimicrob. Agents Chemother. (1993) 37 1207-1213.
27. Rooke R., Tremblay M., Wainberg M.A. AZT (zidovudine) may act postintegrationally to inhibit generation of HIV-1 progeny virus in chronically infected cells. Virology (1990) 176 205-215.
28. Larder B.A., Stammers D.K. Closing in on HIV drug resistance. Nat. Struct. Biol. (1999) 6 103-106.
29. Sarafianos S.G., Das K., Ding J., Boyer P.L., Hughes S.H., Arnold E. Touching the heart of HIV-1 drug resistance: the fingers close down on the dNTP at the polymerase active site. Chem. Biol. (1999) 6 R137-R146.
30. Meyer P.R., Matsuura S.E., Mian A.M., So A.G., Scott W.A. A mechanism of AZT resistance: an increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase. Mol. Cell (1999) 4 35-43.
31. Arion D., Sluis-Cremer N., Parniak M.A. Mechanism by which phosphonoformic acid resistance mutations restore 3′-azido-3′-deoxythymidine (AZT) sensitivity to AZT-resistant HIV-1 reverse transcriptase. J. Biol. Chem. (2000) 275 9251-9255.
32. Garcia-Lerma J.G., MacInnes H., Bennett D., Weinstock H., Heneine W. Transmitted human immunodeficiency virus type 1 carrying the D67N or K219Q/E mutation evolves rapidly to zidovudine resistance in vitro and shows a high replicative fitness in the presence of zidovudine. J. Virol. (2004) 78 7545-7552.
33. Arion D., Parniak M.A. HIV resistance to zidovudine: the role of pyrophosphorolysis. Drug Resist. Updat. (1999) 2 91-95.
34. Jacobo-Molina A., Ding J., Nanni R.G. et al. Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 A resolution shows bent DNA. Proc. Natl Acad. Sci. USA (1993) 90 6320-6324.
35. de Ronde A., van Dooren M., van Der Hoek L. et al. Establishment of new transmissible and drug-sensitive human immunodeficiency virus type 1 wild types due to transmission of nucleoside analogue-resistant virus. J. Virol. (2001) 75 595-602.
36. Garcia-Lerma J.G., Nidtha S., Blumoff K., Weinstock H., Heneine W. Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug-naive persons. Proc. Natl Acad. Sci. USA (2001) 98 13907-13912.
37. Richman D., Rosenthal A.S., Skoog M. et al. BI-RG-587 is active against zidovudine-resistant human immunodeficiency virus type 1 and synergistic with zidovudine. Antimicrob. Agents Chemother. (1991) 35 305-308.
38. Dueweke T.J., Poppe S.M., Romero D.L. et al. U-90152, a potent inhibitor of human immunodeficiency virus type 1 replication. Antimicrob. Agents Chemother. (1993) 37 1127-1131.
39. Seckler J.M., Howard K.J., Barkley M.D., Wintrode P.L. Solution structural dynamics of HIV-1 reverse transcriptase heterodimer. Biochemistry (2009) 48 7646-7655.
40. Balzarini J. Current status of the non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1. Curr. Top. Med. Chem. (2004) 4 921-944.
41. Van Laethem K., Witvrouw M., Balzarini J. et al. Patient HIV-1 strains carrying the multiple nucleoside resistance mutations are cross-resistant to abacavir. AIDS (2000) 14 469-471.
42. Cullen M.D., Ho W.C., Bauman J.D. et al. Crystallographic study of a novel subnanomolar inhibitor provides insight on the binding interactions of alkenyldiarylmethanes with human immunodeficiency virus-1 reverse transcriptase. J. Med. Chem. (2009) 52 6467-6473.
43. Domaoal R.A., Demeter L.M. Structural and biochemical effects of human immunodeficiency virus mutants resistant to non-nucleoside reverse transcriptase inhibitors. Int. J. Biochem. Cell Biol. (2004) 36 1735-1751.
44. Deeks S.G. International perspectives on antiretroviral resistance. Nonnucleoside reverse transcriptase inhibitor resistance. J. Acquir. Immune Defic. Syndr. (2001) 26(Suppl 1) S25-S33.
45. Johnson V.A., Brun-Vezinet F., Clotet B. et al. Update of the drug resistance mutations in HIV-1: 2007. Top. HIV Med. (2007) 15 119-125.
46. Ren J., Nichols C.E., Stamp A. et al. Structural insights into mechanisms of non-nucleoside drug resistance for HIV-1 reverse transcriptases mutated at codons 101 or 138. FEBS J. (2006) 273 3850-3860.
47. Demeter L.M., Shafer R.W., Meehan P.M. et al. Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260). Antimicrob. Agents Chemother. (2000) 44 794-797.
48. Petropoulos C.J., Parkin N.T., Limoli K.L. et al. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob. Agents Chemother. (2000) 44 920-928.
49. Ren J., Nichols C.E., Chamberlain P.P., Weaver K.L., Short S.A., Stammers D.K. Crystal structures of HIV-1 reverse transcriptases mutated at codons 100, 106 and 108 and mechanisms of resistance to non-nucleoside inhibitors. J. Mol. Biol. (2004) 336 569-578.
50. Das K., Sarafianos S.G., Clark A.D. Jr, Boyer P.L., Hughes S.H., Arnold E. Crystal structures of clinically relevant Lys103Asn/Tyr181Cys double mutant HIV-1 reverse transcriptase in complexes with ATP and non-nucleoside inhibitor HBY 097. J. Mol. Biol. (2007) 365 77-89.
51. Ren J., Nichols C.E., Chamberlain P.P. et al. Relationship of potency and resilience to drug resistant mutations for GW420867X revealed by crystal structures of inhibitor complexes for wild-type, Leu100Ile, Lys101Glu, and Tyr188Cys mutant HIV-1 reverse transcriptases. J. Med. Chem. (2007) 50 2301-2309.
52. Bauman J.D., Das K., Ho W.C. et al. Crystal engineering of HIV-1 reverse transcriptase for structure-based drug design. Nucleic Acids Res. (2008) 36 5083-5092.
53. Bacheler L., Jeffrey S., Hanna G. et al. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy. J. Virol. (2001) 75 4999-5008.
54. Conway B., Wainberg M.A., Hall D. et al. Development of drug resistance in patients receiving combinations of zidovudine, didanosine and nevirapine. AIDS (2001) 15 1269-1274.
55. Hanna G.J., Johnson V.A., Kuritzkes D.R. et al. Patterns of resistance mutations selected by treatment of human immunodeficiency virus type 1 infection with zidovudine, didanosine, and nevirapine. J. Infect. Dis. (2000) 181 904-911.
56. Hsiou Y., Ding J., Das K. et al. The Lys103Asn mutation of HIV-1 RT: a novel mechanism of drug resistance. J. Mol. Biol. (2001) 309 437-445.
57. D'Aquila R.T., Schapiro J.M., Brun-Vezinet F. et al. Drug Resistance Mutations in HIV-1. Top. HIV Med. (2002) 10 21-25.
58. Shafer R.W. Genotypic testing for human immunodeficiency virus type 1 drug resistance. Clin. Microbiol. Rev. (2002) 15 247-277.
59. Ceccherini-Silberstein F., Erba F., Gago F. et al. Identification of the minimal conserved structure of HIV-1 protease in the presence and absence of drug pressure. AIDS (2004) 18 F11-F19.
60. Erickson J.W., Gulnik S.V., Markowitz M. Protease inhibitors: resistance, cross-resistance, fitness and the choice of initial and salvage therapies. AIDS (1999) 13(Suppl A) S189-S204.
61. Huff J.R., Kahn J. Discovery and clinical development of HIV-1 protease inhibitors. Adv. Protein Chem. (2001) 56 213-251.
62. Martinez-Cajas J.L., Wainberg M.A. Protease inhibitor resistance in HIV-infected patients: molecular and clinical perspectives. Antiviral Res. (2007) 76 203-221.
63. Velazquez-Campoy A., Muzammil S., Ohtaka H., Schon A., Vega S., Freire E. Structural and thermodynamic basis of resistance to HIV-1 protease inhibition: implications for inhibitor design. Curr. Drug Targets Infect. Disord. (2003) 3 311-328.
64. Perryman A.L., Lin J.H., McCammon J.A. HIV-1 protease molecular dynamics of a wild-type and of the V82F/I84V mutant: possible contributions to drug resistance and a potential new target site for drugs. Protein Sci. (2004) 13 1108-1123.
65. Gonzales M.J., Machekano R.N., Shafer R.W. Human immunodeficiency virus type 1 reverse-transcriptase and protease subtypes: classification, amino acid mutation patterns, and prevalence in a northern California clinic-based population. J. Infect. Dis. (2001) 184 998-1006.
66. Tupinambas U., Aleixo A., Greco D. HIV-1 genotypes related to failure of nelfinavir as the first protease inhibitor treatment. Braz. J. Infect. Dis. (2005) 9 324-329.
67. Dronda F., Casado J.L., Moreno S. et al. Phenotypic cross-resistance to nelfinavir: the role of prior antiretroviral therapy and the number of mutations in the protease gene. AIDS Res. Hum. Retroviruses (2001) 17 211-215.
68. Falloon J., Piscitelli S., Vogel S. et al. Combination therapy with amprenavir, abacavir, and efavirenz in human immunodeficiency virus (HIV)-infected patients failing a protease-inhibitor regimen: pharmacokinetic drug interactions and antiviral activity. Clin. Infect. Dis. (2000) 30 313-318.
69. Hertogs K., Bloor S., Kemp S.D. et al. Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: a survey of over 6000 samples. AIDS (2000) 14 1203-1210.
70. Para M.F., Glidden D.V., Coombs R.W. et al. Baseline human immunodeficiency virus type 1 phenotype, genotype, and RNA response after switching from long-term hard-capsule saquinavir to indinavir or soft-gel-capsule saquinavir in AIDS clinical trials group protocol 333. J. Infect. Dis. (2000) 182 733-743.
71. Cote H.C., Brumme Z.L., Harrigan P.R. Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and/or saquinavir. J. Virol. (2001) 75 589-594.
72. Kaufmann G.R., Suzuki K., Cunningham P. et al. Impact of HIV type 1 protease, reverse transcriptase, cleavage site, and p6 mutations on the virological response to quadruple therapy with saquinavir, ritonavir, and two nucleoside analogs. AIDS Res. Hum. Retroviruses (2001) 17 487-497.
73. Banke S., Lillemark M.R., Gerstoft J., Obel N., Jorgensen L.B. Positive selection pressure introduces secondary mutations at Gag cleavage sites in human immunodeficiency virus type 1 harboring major protease resistance mutations. J. Virol. (2009) 83 8916-8924.
74. Condra J.H., Schleif W.A., Blahy O.M. et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature (1995) 374 569-571.
75. Mammano F., Trouplin V., Zennou V., Clavel F. Retracing the evolutionary pathways of human immunodeficiency virus type 1 resistance to protease inhibitors: virus fitness in the absence and in the presence of drug. J. Virol. (2000) 74 8524-8531.
76. Kantor R., Fessel W.J., Zolopa A.R. et al. Evolution of primary protease inhibitor resistance mutations during protease inhibitor salvage therapy. Antimicrob. Agents Chemother. (2002) 46 1086-1092.
77. Martinez-Picado J., Savara A.V., Sutton L., D'Aquila R.T. Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1. J. Virol. (1999) 73 3744-3752.
78. Eastman P.S., Mittler J., Kelso R. et al. Genotypic changes in human immunodeficiency virus type 1 associated with loss of suppression of plasma viral RNA levels in subjects treated with ritonavir (Norvir) monotherapy. J. Virol. (1998) 72 5154-5164.
79. Sune C., Brennan L., Stover D.R., Klimkait T. Effect of polymorphisms on the replicative capacity of protease inhibitor-resistant HIV-1 variants under drug pressure. Clin. Microbiol. Infect. (2004) 10 119-126.
80. Condra J.H., Holder D.J., Schleif W.A. et al. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J. Virol. (1996) 70 8270-8276.
81. Kempf D.J., Isaacson J.D., King M.S. et al. Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients. J. Virol. (2001) 75 7462-7469.
82. Pieniazek D., Rayfield M., Hu D.J. et al. Protease sequences from HIV-1 group M subtypes A-H reveal distinct amino acid mutation patterns associated with protease resistance in protease inhibitor-naive individuals worldwide. HIV Variant Working Group. AIDS (2000) 14 1489-1495.
83. Kantor R., Machekano R., Gonzales M.J., Dupnik K., Schapiro J.M., Shafer R.W. Human Immunodeficiency Virus Reverse Transcriptase and Protease Sequence Database: an expanded data model integrating natural language text and sequence analysis programs. Nucleic Acids Res. (2001) 29 296-299.
84. Craigie R. HIV integrase, a brief overview from chemistry to therapeutics. J. Biol. Chem. (2001) 276 23213-23216.
85. Neamati N. Dipyrimidine-based inhibitors of HIV-1 integrase. Expert Opin. Investig. Drugs (2003) 12 289-292.
86. Neamati N. Structure-based HIV-1 integrase inhibitor design: a future perspective. Expert Opin. Investig. Drugs (2001) 10 281-296.
87. Hazuda D.J., Felock P., Witmer M. et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science (2000) 287 646-650.
88. Ceccherini-Silberstein F., Malet I., D'Arrigo R., Antinori A., Marcelin A.G., Perno C.F. Characterization and structural analysis of HIV-1 integrase conservation. AIDS Rev. (2009) 11 17-29.
89. Espeseth A.S., Felock P., Wolfe A. et al. HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase. Proc. Natl Acad. Sci. USA (2000) 97 11244-11249.
90. Grobler J.A., Stillmock K., Hu B. et al. Diketo acid inhibitor mechanism and HIV-1 integrase: implications for metal binding in the active site of phosphotransferase enzymes. Proc. Natl Acad. Sci. USA (2002) 99 6661-6666.
91. Hazuda D.J., Young S.D., Guare J.P. et al. Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques. Science (2004) 305 528-532.
92. Yi Y., Loftin L., Wang L., Ratcliffe S.J., Isaacman-Beck J., Collman R.G. Entry coreceptor use and fusion inhibitor T20 sensitivity of dual-tropic R5X4 HIV-1 in primary macrophage infection. J. Acquir. Immune Defic. Syndr. (2008) 47 285-292.
93. Ray N., Blackburn L.A., Doms R.W. HR-2 mutations in human immunodeficiency virus type 1 gp41 restore fusion kinetics delayed by HR-1 mutations that cause clinical resistance to enfuvirtide. J. Virol. (2009) 83 2989-2995.
94. Chen R.Y., Kilby J.M., Saag M.S. Enfuvirtide. Expert Opin. Investig. Drugs. (2002) 11 1837-1843.
95. Kilby J.M., Eron J.J. Novel therapies based on mechanisms of HIV-1 cell entry. N. Engl. J. Med. (2003) 348 2228-2238.
96. LaBonte J., Lebbos J., Kirkpatrick P. Enfuvirtide. Nat. Rev. Drug Discov. (2003) 2 345-346.
97. Moyle G. Stopping HIV fusion with enfuvirtide: the first step to extracellular HAART. J. Antimicrob. Chemother. (2003) 51 213-217.
98. Reeves J.D., Gallo S.A., Ahmad N. et al. Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics. Proc. Natl Acad. Sci. USA (2002) 99 16249-16254.
99. Xu L., Hue S., Taylor S. et al. Minimal variation in T-20 binding domain of different HIV-1 subtypes from antiretroviral-naive and -experienced patients. AIDS (2002) 16 1684-1686.
100. Kilby J.M., Lalezari J.P., Eron J.J. et al. The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults. AIDS Res. Hum. Retroviruses (2002) 18 685-693.
101. Lalezari J.P., Henry K., O'Hearn M. et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N. Engl. J. Med. (2003) 348 2175-2185.
102. Lalezari J.P., Eron J.J., Carlson M. et al. A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy. AIDS (2003) 17 691-698.
103. Lazzarin A., Clotet B., Cooper D. et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N. Engl. J. Med. (2003) 348 2186-2195.
104. Witvrouw M., Pannecouque C., Switzer W.M., Folks T.M., De Clercq E., Heneine W. Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis. Antivir. Ther. (2004) 9 57-65.
105. Fatkenheuer G., Pozniak A.L., Johnson M.A. et al. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat. Med. (2005) 11 1170-1172.
106. Gulick R.M., Su Z., Flexner C. et al. Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211. J. Infect. Dis. (2007) 196 304-312.
107. De Clercq E. New anti-HIV agents and targets. Med. Res. Rev. (2002) 22 531-565.
108. Wilkin T.J., Su Z., Kuritzkes D.R. et al. HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211. Clin. Infect. Dis. (2007) 44 591-595.
109. Shaheen F., Collman R.G. Co-receptor antagonists as HIV-1 entry inhibitors. Curr. Opin. Infect. Dis. (2004) 17 7-16.
110. Baba M., Nishimura O., Kanzaki N. et al. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc. Natl Acad. Sci. USA (1999) 96 5698-5703.
111. Brumme Z.L., Goodrich J., Mayer H.B. et al. Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals. J. Infect. Dis. (2005) 192 466-474.
112. Melby T., Despirito M., Demasi R., Heilek-Snyder G., Greenberg M.L., Graham N. HIV-1 coreceptor use in triple-class treatment-experienced patients: baseline prevalence, correlates, and relationship to enfuvirtide response. J. Infect. Dis. (2006) 194 238-246.
113. Moyle G.J., Wildfire A., Mandalia S. et al. Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection. J. Infect. Dis. (2005) 191 866-872.
114. Harrison J.E., Lynch J.B., Sierra L.J. et al. Baseline resistance of primary human immunodeficiency virus type 1 strains to the CXCR4 inhibitor AMD3100. J. Virol. (2008) 82 11695-11704.
115. Arakaki R., Tamamura H., Premanathan M. et al. T134, a small-molecule CXCR4 inhibitor, has no cross-drug resistance with AMD3100, a CXCR4 antagonist with a different structure. J. Virol. (1999) 73 1719-1723.
116. Weinstock H., Respess R., Heneine W. et al. Prevalence of mutations associated with reduced antiretroviral drug susceptibility among human immunodeficiency virus type 1 seroconverters in the United States, 1993-1998. J. Infect. Dis. (2000) 182 330-333.
117. Puig T., Perez-Olmeda M., Rubio A. et al. Prevalence of genotypic resistance to nucleoside analogues and protease inhibitors in Spain. The ERASE-2 Study Group. AIDS (2000) 14 727-732.
118. Havlir D.V., Hellmann N.S., Petropoulos C.J. et al. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens. JAMA (2000) 283 229-234.
119. Harrigan P.R., Hogg R.S., Dong W.W. et al. Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. J. Infect. Dis. (2005) 191 339-347.
120. Aleman S., Soderbarg K., Visco-Comandini U., Sitbon G., Sonnerborg A. Drug resistance at low viraemia in HIV-1-infected patients with antiretroviral combination therapy. AIDS (2002) 16 1039-1044.
121. Idemyor V. Human immunodeficiency viruses and drug therapy: resistance and implications for antiretroviral therapy. Pharmacotherapy (2002) 22 659-662.
122. Duwe S., Brunn M., Altmann D. et al. Frequency of genotypic and phenotypic drug-resistant HIV-1 among therapy-naive patients of the German Seroconverter Study. J. Acquir. Immune Defic. Syndr. (2001) 26 266-273.
123. Brenner B., Wainberg M.A., Salomon H. et al. Resistance to antiretroviral drugs in patients with primary HIV-1 infection. Investigators of the Quebec Primary Infection Study. Int. J. Antimicrob. Agents (2000) 16 429-434.
124. Little S.J., Holte S., Routy J.P. et al. Antiretroviral-drug resistance among patients recently infected with HIV. N. Engl. J. Med. (2002) 347 385-394.
125. Grant R.M., Hecht F.M., Warmerdam M. et al. Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA (2002) 288 181-188.
126. Barbour J.D., Hecht F.M., Wrin T. et al. Persistence of primary drug resistance among recently HIV-1 infected adults. AIDS (2004) 18 1683-1689.
127. Oette M., Kaiser R., Daumer M. et al. Primary drug-resistance in HIV-positive patients on initiation of first-line antiretroviral therapy in Germany. Eur. J. Med. Res. (2004) 9 273-278.
128. Tanuri A., Caridea E., Dantas M.C. et al. Prevalence of mutations related to HIV-1 antiretroviral resistance in Brazilian patients failing HAART. J. Clin. Virol. (2002) 25 39-46.
129. Wegner S.A., Brodine S.K., Mascola J.R. et al. Prevalence of genotypic and phenotypic resistance to anti-retroviral drugs in a cohort of therapy-naive HIV-1 infected US military personnel. AIDS (2000) 14 1009-1015.
130. Salomon H., Wainberg M.A., Brenner B. et al. Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use. Investigators of the Quebec Primary Infection Study. AIDS (2000) 14 F17-F23.
131. Taylor S., Cane P., Hue S. et al. Identification of a transmission chain of HIV type 1 containing drug resistance-associated mutations. AIDS Res. Hum. Retroviruses (2003) 19 353-361.
132. Ammaranond P., Cunningham P., Oelrichs R. et al. Rates of transmission of antiretroviral drug resistant strains of HIV-1. J. Clin. Virol. (2003) 26 153-161.
133. Gandhi R.T., Wurcel A., Rosenberg E.S. et al. Progressive reversion of human immunodeficiency virus type 1 resistance mutations in vivo after transmission of a multiply drug-resistant virus. Clin. Infect. Dis. (2003) 37 1693-1698.
134. Wainberg M.A., Friedland G. Public health implications of antiretroviral therapy and HIV drug resistance. JAMA (1998) 279 1977-1983.
135. Palmer S., Shafer R.W., Merigan T.C. Highly drug-resistant HIV-1 clinical isolates are cross-resistant to many antiretroviral compounds in current clinical development. AIDS (1999) 13 661-667.
136. Loveday C. International perspectives on antiretroviral resistance. Nucleoside reverse transcriptase inhibitor resistance. J. Acquir. Immune Defic. Syndr. (2001) 26(Suppl 1) S10-S24.
137. Miller V. International perspectives on antiretroviral resistance. Resistance to protease inhibitors. J. Acquir. Immune Defic. Syndr. (2001) 26(Suppl 1) S34-S50.
138. Hirsch M.S., Conway B., D'Aquila R.T. et al. Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society - USA Panel. JAMA (1998) 279 1984-1991.
139. D'Aquila R.T., Schapiro J.M., Brun-Vezinet F. et al. Drug resistance mutations in HIV-1. Top. HIV Med. (2003) 11 92-96.
140. Blower S.M., Aschenbach A.N., Gershengorn H.B., Kahn J.O. Predicting the unpredictable: transmission of drug-resistant HIV. Nat. Med. (2001) 7 1016-1020.
141. Opravil M., Hirschel B., Lazzarin A. et al. A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection. J. Infect. Dis. (2002) 185 1251-1260.
142. Hirsch M.S., Brun-Vezinet F., Clotet B. et al. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin. Infect. Dis. (2003) 37 113-128.
143. Bangsberg D.R., Perry S., Charlebois E.D. et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS (2001) 15 1181-1183.
144. Louie M., Hogan C., Di Mascio M. et al. Determining the relative efficacy of highly active antiretroviral therapy. J. Infect. Dis. (2003) 187 896-900.
145. Kirk O., Pedersen C., Law M. et al. Analysis of virological efficacy in trials of antiretroviral regimens: drawbacks of not including viral load measurements after premature discontinuation of therapy. Antivir. Ther. (2002) 7 271-281.
146. Volberding P. Adherence, resistance, and timing: current issues in the use of new therapies. AIDS Read. (2002) 12 349-350, 56-57, 68.
147. Hogg R.S., Heath K., Bangsberg D. et al. Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1year of follow-up. AIDS (2002) 16 1051-1058.
148. Masuhr A., Mueller M., Simon V. et al. Predictors of treatment failure during highly active antiretroviral therapy (racing trial). Eur. J. Med. Res. (2002) 7 341-346.
149. Walsh J.C., Pozniak A.L., Nelson M.R., Mandalia S., Gazzard B.G. Virologic rebound on HAART in the context of low treatment adherence is associated with a low prevalence of antiretroviral drug resistance. J. Acquir. Immune Defic. Syndr. (2002) 30 278-287.
150. Briones C., Perez-Olmeda M., Rodriguez C., del Romero J., Hertogs K., Soriano V. Primary genotypic and phenotypic HIV-1 drug resistance in recent seroconverters in Madrid. J. Acquir. Immune Defic. Syndr. (2001) 26 145-150.
151. Delgado E., Leon-Ponte M., Villahermosa M.L. et al. Analysis of HIV type 1 protease and reverse transcriptase sequences from Venezuela for drug resistance-associated mutations and subtype classification: a UNAIDS study. AIDS Res. Hum. Retroviruses (2001) 17 753-758.
152. Gallego O., Ruiz L., Vallejo A. et al. Changes in the rate of genotypic resistance to antiretroviral drugs in Spain. AIDS (2001) 15 1894-1896.
153. Goudsmit J., Weverling G.J., van der Hoek L. et al. Carrier rate of zidovudine-resistant HIV-1: the impact of failing therapy on transmission of resistant strains. AIDS (2001) 15 2293-2301.
154. Schmit J.C., Van Laethem K., Ruiz L. et al. Multiple dideoxynucleoside analogue-resistant (MddNR) HIV-1 strains isolated from patients from different European countries. AIDS (1998) 12 2007-2015.
155. Richman D.D., Morton S.C., Wrin T. et al. The prevalence of antiretroviral drug resistance in the United States. AIDS (2004) 18 1393-1401.
156. Brenner B.G., Turner D., Wainberg M.A. HIV-1 drug resistance: can we overcome? Expert Opin. Biol. Ther. (2002) 2 751-761.
157. Imrie A., Beveridge A., Genn W., Vizzard J., Cooper D.A. Transmission of human immunodeficiency virus type 1 resistant to nevirapine and zidovudine. Sydney Primary HIV Infection Study Group. J. Infect. Dis. (1997) 175 1502-1506.
158. Kuritzkes D.R., Sevin A., Young B. et al. Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine-lamivudine-ritonavir: genotypic analysis of human immunodeficiency virus type 1 isolates from AIDS clinical trials group protocol 315.ACTG Protocol 315 Team. J. Infect. Dis. (2000) 181 491-497.
159. Izopet J., Massip P., Souyris C. et al. Shift in HIV resistance genotype after treatment interruption and short-term antiviral effect following a new salvage regimen. AIDS (2000) 14 2247-2255.
160. Hirsch M.S., Brun-Vezinet F., D'Aquila R.T. et al. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. JAMA (2000) 283 2417-2426.
161. Hirsch M., G nthard H., Schapiro J. et al. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin. Infect. Dis. (2008) 47 266-285.
162. Yerly S., Kaiser L., Race E., Bru J.P., Clavel F., Perrin L. Transmission of antiretroviral-drug-resistant HIV-1 variants. Lancet (1999) 354 729-733.
163. Little S.J., Daar E.S., D'Aquila R.T. et al. Reduced antiretroviral drug susceptibility among patients with primary HIV infection. JAMA (1999) 282 1142-1149.
164. Scott P., Arnold E., Evans B. et al. Surveillance of HIV antiretroviral drug resistance in treated individuals in England: 1998-2000. J. Antimicrob. Chemother. (2004) 53 469-473.
165. Tesoriero J., French T., Weiss L., Waters M., Finkelstein R., Agins B. Stability of adherence to highly active antiretroviral therapy over time among clients enrolled in the treatment adherence demonstration project. J. Acquir. Immune Defic. Syndr. (2003) 33 484-493.
166. Katz M.H., Schwarcz S.K., Kellogg T.A. et al. Impact of highly active antiretroviral treatment on HIV seroincidence among men who have sex with men: San Francisco. Am. J. Public Health (2002) 92 388-394.
167. Wensing A.M., Boucher C.A. Worldwide transmission of drug-resistant HIV. AIDS Rev. (2003) 5 140-155.
168. Grossman Z., Lorber M., Maayan S. et al. Drug-resistant HIV infection among drug-naive patients in Israel. Clin. Infect. Dis. (2005) 40 294-302.